GLG welcomes Dr. Grunvald to discuss:
- Consumer behavior impact of GLP-1s: caloric intake and food palette changes, reduction of comorbidities, fitness and activity routines
- Implications of recent data publications: SELECT, SURMOUNT-4
- Outlook for GLP-1s as a class: Zepbound vs. Wegovy utilization, implications for an oral delivery option, maintenance therapy, long term usage
Biography:
Dr. Eduardo Grunvald is a board-certified internal medicine and obesity medicine doctor currently serving as Medical Director in the USCD Weight Management Program at the University of California, San Diego. Dr. Grunvald is integrally involved in managing patients going through surgical and non-surgical weight loss efforts. He is the obesity medicine physician for the UC San Diego Bariatric and Metabolic Institute and medical director for its Center for Advanced Weight Management. As a board-certified obesity medicine specialist, he works with all aspects of obesity and related problems. As a clinical professor of medicine, Dr. Grunvald is involved in training medical students, residents, and fellows at UC San Diego School of Medicine. He is involved in researching all aspects of obesity including education, bias, drug therapy, surgical therapy, and comorbidities.
Please note, Dr. Eduardo Grunvald will not discuss his advisory work for Novo Nordisk in any capacity. He also holds stock shares in Novo Nordisk. He may have additional limitations on what he is permitted to discuss and will decline to answer questions related to confidential matters.
Additionally, this event will be recorded. Attendees who ask questions or make comments will not be identified (either by name or affiliation.)